Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.3520
+0.0020 (0.57%)
Apr 15, 2026, 4:00 PM EST
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the twelve months ending December 31, 2025, down -91.86% year-over-year. In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K, down -87.00%.
Revenue (ttm)
158.08K CAD
Revenue Growth
-91.86%
P/S Ratio
207.59
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.93M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionArch Biopartners News
- 14 days ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 17 days ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 23 days ago - Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial - GlobeNewsWire
- 27 days ago - Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide - GlobeNewsWire
- 2 months ago - Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease - GlobeNewsWire
- 4 months ago - Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide - GlobeNewsWire
- 7 months ago - Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) - GlobeNewsWire
- 9 months ago - Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury - GlobeNewsWire